伊克力西斯 EXEL 深 滬
已收盤 09-05 16:00:00 美东时间
37.88
+0.500
+1.34%
華盛通- 最 高37.93
- 今 開37.51
- 成交量 252.46万股
- 最 低 37.215
- 昨 收 37.38
- 總市值 101.90亿
- 52周最高 49.62
- 市盈率 靜 21.52
- 換手率 0.94%
- 52周最低 25.174
- 委 比 1.43%
- 總股本 2.69亿
- 歷史最高 49.62
- 量 比 0.90
- 振 幅 1.91%
- 歷史最低 1.26
- 每 手 1
- 風險率 5.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Exelixis shuttering Pennsylvania site, laying off 130 employees
Exelixis (NASDAQ:EXEL) is shutting down a facility in King of Prussia, Pa., to focus its operations at its headquarters in Alameda, Calif. As a result, 130 employees will be laid off, according to Fie...
09-04 22:19
Exelixis Announces New Executive VP for R&D
Exelixis ( ($EXEL) ) has issued an announcement. On August 29, 2025, Exelixis, ...
08-30 05:29
Is the Market Bullish or Bearish on Exelixis?
Exelixis's (NYSE:EXEL) short percent of float has fallen 3.26% since its last r...
08-26 23:01
The Analyst Verdict: Exelixis In The Eyes Of 19 Experts
19 analysts have shared their evaluations of Exelixis (NASDAQ:EXEL) during the ...
08-13 05:00
HC Wainwright & Co. Maintains Buy on Exelixis, Lowers Price Target to $46
HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and lowers the price target from $53 to $46.
08-12 20:10
美股大行评级 | 潜在涨幅36%！花旗上调Coinbase目标价升至505美元；摩根大通维持迪士尼"超配"评级，目标价升至138美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从41美元升至46美元；杰富瑞：维持Kiniksa Pharmaceuticals"买入"评级，目标价从45美元升至54美元
07-30 09:36
Assessing Exelixis: Insights From 20 Financial Analysts
In the last three months, 20 analysts have published ratings on Exelixis (NASDA...
07-30 03:03
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.
07-30 01:27
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans
Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update.
07-30 00:32
